Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week teduglutide study in parenteral nutrition-dependent short bowel syndrome
2008-006193-15Phase 3Completed
- Sponsor
- NPS Pharmaceuticals, Inc.
- Start
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in short bowel syndrome (SBS) comparing Teduglutide with Placebo (2 arms). Primary endpoint: Response at Week 20 maintained through Week 24. Started Jan 2009; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2008-006193-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006193-15.